New research on fillers and non-surgical aesthetics after GLP-1 weight loss
Allergan Aesthetics (AbbVie) presented 9 abstracts at ASDS 2026 in San Diego (5–8 November).
Allergan Aesthetics (AbbVie) presented 9 abstracts at ASDS 2026 in San Diego (5–8 November).
US cosmetic surgical procedures rose 7% in 2025, according to the American Society of Plastic Surgeons (ASPS).
Australia's Therapeutic Goods Administration has approved a once-daily oral tablet form of semaglutide, sold as Wegovy.
Apothecary Pharma is recalling 22 vials of compounded tirzepatide and one vial of NAD+ injection because their sterility cannot be assured.
Galderma, L'Oréal and Natura are testing treatments for facial sagging and volume loss in weight-loss drug users.
On 16 October 2026 the EMA's human medicines committee recommended authorising Foundayo (orforglipron) in the EU.
The UK medicines regulator and West Midlands Police seized more than 12,000 fake weight-loss pens in a raid on 14 October 2026.
A systematic review in Plastic and Reconstructive Surgery pooled 12 studies with 29,357 patients.
The Journal of Dental Research published a critical review of GLP-1 drugs and oral health.
Nothing more to show